Revenue and Profitability - Revenue for Q1 2023 was CNY 112.68 million, a decrease of 8.33% compared to CNY 122.93 million in the same period last year[5] - Net profit attributable to shareholders was CNY 22.12 million, an increase of 1.54% from CNY 21.78 million year-on-year[5] - Total operating revenue for Q1 2023 was ¥112,684,910.79, a decrease of 8.5% compared to ¥122,927,958.21 in Q1 2022[16] - Net profit for Q1 2023 increased to ¥24,073,789.17, up 12.7% from ¥21,363,230.14 in Q1 2022[18] - The total comprehensive income for Q1 2023 was ¥25,804,745.59, compared to ¥20,843,673.76 in Q1 2022, indicating a growth of 24%[18] Cash Flow and Financial Position - Net cash flow from operating activities decreased by 65.55% to CNY 8.51 million, down from CNY 24.69 million in Q1 2022, primarily due to reduced sales receipts[8] - The company's cash and cash equivalents decreased by CNY 245,729.79, contrasting with an increase of CNY 17.72 million in Q1 2022[8] - The cash and cash equivalents at the end of Q1 2023 were ¥120,070,051.16, down from ¥177,024,470.99 at the end of Q1 2022[22] - The net cash flow from operating activities was ¥8,507,031.19, down 65.5% from ¥24,690,382.91 in the previous year[21] - The company reported a net cash outflow from investing activities of ¥5,714,848.55, compared to a net outflow of ¥2,369,821.21 in the previous year[21] Assets and Liabilities - Total assets increased by 3.50% to CNY 693.67 million compared to CNY 670.21 million at the end of the previous year[5] - The total assets of Guanhao Biotechnology Co., Ltd. as of the end of Q1 2023 amounted to RMB 693,670,565.52, an increase from RMB 670,209,400.26 at the beginning of the year[14] - The company's current assets increased to RMB 324,503,050.37 from RMB 298,889,385.35, reflecting a growth of approximately 8.5%[14] - The total liabilities decreased slightly to RMB 236,985,727.49 from RMB 239,329,307.83, a reduction of approximately 1.4%[15] - The total equity attributable to the parent company increased to RMB 509,156,430.90 from RMB 485,310,208.77, reflecting a growth of approximately 4.9%[15] Accounts Receivable and Expenses - Accounts receivable increased by 38.39% to CNY 99.60 million, attributed to extended credit terms for high-value clients[7] - Accounts receivable rose significantly to RMB 99,604,610.47, up from RMB 71,975,751.81, indicating an increase of about 38.4%[14] - The company reported a decrease in sales expenses to ¥36,778,009.09 from ¥41,645,417.64, a reduction of 11.5%[16] - The company reported a 61.50% reduction in financial expenses, decreasing to CNY 487,811.41 due to a decrease in loan scale and interest[7] - Research and development expenses remained stable at ¥9,567,734.69, slightly down from ¥9,770,941.24[16] Shareholder Information and Corporate Actions - The number of ordinary shareholders at the end of the reporting period was 29,770, with the largest shareholder holding 20.76% of the shares[9] - The company has received approval for a specific stock issuance to targeted investors, as per the resolutions from the board and shareholder meetings[11] Legal Matters - The company is currently involved in a significant lawsuit, with the case still under trial as of the report date[12]

出席本次年度业绩网上说明会的人员有： 董事长张永明先生 证券代码：300238 证券简称：冠昊生物 公告编号：2023-026 冠昊生物科技股份有限公司 关于召开 2022 年度业绩网上说明会的公告 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 冠昊生物科技股份有限公司（以下简称"公司"）《2022 年年度报告全文》 及其摘要经公司第五届董事会第十六次会议和第五届监事会第十三次会议审议 通过，于 2023 年 4 月 20 日刊登在中国证监会指定的创业板信息披露网站上，根 据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等有关规定，公司定于 2023 年 5 月 5 日下午 15:00 至 17:00 通过远程网络方式召开 2022 年度业绩网上说明会，投资 者可登陆"价值在线"（www.ir-online.cn）参与本次年度业绩说明会。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 ...

证券代码：300238 证券简称：冠昊生物 冠昊生物科技股份有限公司 投资者关系活动记录表 编号：2015-002 | --- | --- | --- | |----------------|------------------------|-----------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | 类别 | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ 其他 | | | | 广证恒生：唐爱金 | | | | 冠丰资产：杨欢 | | | 参与单位名称及 | 西域投资：李季馥 | | | 人员姓名 | 国联证券：刘生平 | | | | 创金合信基金：皮劲松 | | | | 华润元大基金：张磊 | | | 时间 | 2015-8-28 上午 | 10:00-11:30 | | 地点 | 公司 507 会议室 | | | | | 副总经理、财务负责人兼董事会秘书 周利军先生 | | 上市公司接待人 | 证券事务代表 | 胡珺女士 | | 员 ...

证券代码：300238 证券简称：冠昊生物 广东冠昊生物科技股份有限公司 投资者关系活动记录表 编号：2015-001 | --- | --- | --- | |----------------|-------------------------------------|----------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 金鹰基金：陈立、方超 | | | 人员姓名 | 华夏基金：邓湘伟 | | | | | | | 时间 | 2015-3-11 上午 2015-3-12 上午 | 10:00-11:30 10:30-12:00 | | 地点 | 公司 404 会议室 | | | | | 副总经理、财务负责人兼董事会秘书 周利军先生 | | 上市公司接待人 | 证券事务代表 | 胡珺女士 | | 员姓名 | 董事会办公室 | ...

编号：2016-003 证券代码：300238 证券简称：冠昊生物 冠昊生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|---------------------|----------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动 | | □媒体采访 □业绩说明会 | | 类别 | □ | 新闻发布会 □路演活动 | | | □现场参观 | | | | □ 其他 | | | 参与单位名称及 | 东方基金等 4 | 名机构投资者联合调研 | | 人员姓名 | | | | 时间 | 2016-6-14 下午 | 16:00-17:00 | | 地点 | 公司 404 会议室 | | | 上市公司接待人 | | 副总经理、财务负责人兼董事会秘书 周利军先生 | | 员姓名 | 投资者关系主管 | 陈茜女士 | | 投资者关系活动 | | 本次活动主要采用解答投资者提问的方式进行，本次活 | | 主要内容介绍 | 动的会谈纪要如下： | | ...